Orlando, FL (PRWEB) March 19, 2013
The medication safety advocates at DrugRisks.com are announcing updated information on the site for patients taking the blood thinner Pradaxa. A study released last week at the American College of Cardiology suggests the drug may have higher risks than its counterpart warfarin.
DrugRisks was created to provide those taking popular prescription drugs with the latest safety alerts, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice for current litigation.
Health experts have voiced disagreement over whether those taking Pradaxa to prevent strokes in atrial fibrillation face higher risks for internal bleeding. The FDA recently updated its information to state the drug has the same risks as warfarin*.
However, the Institute for Safe Medication Practices has ranked blood thinners like Pradaxa among the most dangerous drugs, and warned that patients with bleeding from Pradaxa were nearly 5 times as likely to die than those with bleeding from warfarin**.
Now, DrugRisks has learned that researchers from the University of Illinois at Chicago presented a study to the American College of Cardiology last week which warned that the data used by the FDA may be flawed, and the risk for bleeding from Pradaxa may be higher than previously thought***.
Due to the number of patients who have filed a Pradaxa lawsuit over allegations of internal bleeding, cases have been consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to speak with a lawyer about their legal options. Since federal drug injury cases can be very specialized, DrugRisks only recommends lawyers who have already handled Pradaxa lawsuits.
**Instutute for Safe Medication Practices, 1/9/13; ismp.org/quarterwatch/pdfs/2012Q2.pdf